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Background: Burkholderia cepacia complex (Bcc) organisms produce a wide variety of potential virulence factors, including exopolysaccharides
(EPS), and exhibit intrinsic resistance towards many antibiotics. In the present study we investigated the contribution of Bcc bioﬁlm matrix
components, including extracellular DNA, cepacian and poly-β-1,6-N-acetylglucosamine, to tobramycin susceptibility.
Methods: The in vitro bactericidal activity of tobramycin in combination with recombinant human DNase (rhDNase), NaClO and dispersin B was
tested against Bcc bioﬁlms.
Results: EPS degradation by NaClO pretreatment and speciﬁc PNAG degradation by dispersin B signiﬁcantly increased the bactericidal effect of
tobramycin towards some of the Bcc bioﬁlms tested, including the strains of Burkholderia cenocepacia, B. cepacia and Burkholderia metallica.
The presence of rhDNase during bioﬁlm treatment and/or development had no inﬂuence on tobramycin activity.
Conclusion: These results suggest that EPS play a role in tobramycin susceptibility of Bcc bioﬁlms and that matrix degrading combination therapy
could improve treatment of Bcc bioﬁlm infections.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Burkholderia cepacia complex; Bioﬁlm; Tobramycin; Matrix; Cepacian; PNAG1. Introduction
Chronic Pseudomonas aeruginosa lung infections are the
primary cause of morbidity and mortality in CF patients [1].
Although P. aeruginosa is the dominant pathogen isolated from
the chronically infected CF lung, infections with Burkholderia
cepacia complex (Bcc) species often lead to a more rapid
decline in lung function, resulting in increased mortality [2].
Chronic Bcc infections are very difficult to eradicate because of
the capacity of Bcc species to cause invasive disease and their
high level of intrinsic antibiotic resistance. The production of
different exopolymeric substances by mucoid Bcc bacteria
provides additional protection against both antibiotics and host
immune components [3]. Exopolysaccharides (EPS) produced by
Burkholderia cenocepacia have been shown to inhibit neutrophil⁎ Corresponding author. Tel.: +32 92648141; fax: +32 92648195.
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http://dx.doi.org/10.1016/j.jcf.2013.07.004chemotaxis and to reduce the levels of neutrophil derived reactive
oxygen species (ROS) [4]. This reduction in ROS levels is
caused by the ROS-scavenging capacities of these EPSmolecules
[4]. Cuzzi et al. observed a protective effect of cepacian, a Bcc
specific EPS, against hypochlorite (ClO−), a highly bactericidal
ROS produced by neutrophils. This protective effect was also
provided by scavenging, resulting in extensive deacetylation of
cepacian followed by the degradation of the polysaccharide
backbone [5]. Although cepacian is the most common EPS
produced by Bcc species, the production of at least six other
polysaccharides, either synthesized alone or in combination with
cepacian, has been demonstrated [6]. Burkholderia vietnamiensis
LMG 10929, used in this study, has been shown not to produce
cepacian as main EPS but a polysaccharide containing a fucose
residue in its backbone. In addition, the production of poly-β-
1,6-N-acetylglucosamine (PNAG), also known as “polysaccha-
ride intercellular adhesin” (PIA), an important virulence factor
and major constituent of staphylococcal biofilms, has beenby Elsevier B.V. All rights reserved.
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be a minor component compared to cepacian it seems essential
for initiating biofilm formation as well as maintaining biofilm
integrity. Apart from EPS, another important constituent of the
biofilm matrix is extracellular DNA (eDNA). Most research
about the contribution of eDNA to biofilm formation and resis-
tance has focused on P. aeruginosa in which eDNA appears to be
essential for the formation and stabilization of a complex biofilm
structure [8]. Witchurch et al. first demonstrated a reduction in
P. aeruginosa biofilm formation in the presence of DNase.
Subsequently, the contribution of eDNA to biofilm formation
of a variety of bacterial species, including Staphylococcus
epidermidis and Staphylococcus aureus, was investigated [9–11].
In P. aeruginosa and Salmonella enterica biofilms the contribution
of eDNA to aminoglycoside tolerance has already been shown. By
binding divalent cations, a cation-limited environment is created
which in turn induces the expression of pmr genes conferring
resistance towards aminoglycosides [12,13]. In addition, Chiang
et al. observed a shielding effect of eDNA in P. aeruginosa
biofilms, mediating a delayed penetration of aminoglycosides [14].
Still, little is known about the role of eDNA in Burkholderia
biofilms, although it seems to be essential for cellular aggregation
in Burkholderia thailandensis [15].
The aim of the present study was to investigate whether Bcc
biofilm matrix components, including eDNA, cepacian and
PNAG play a role in the protection of biofilm cells against
tobramycin. To this end, the bactericidal effect of tobramycin in
combination with matrix degrading components (rhDNase,
NaClO and dispersin B) was tested against several in vitro
grown Bcc biofilms and compared with the bactericidal effect
of tobramycin alone.2. Materials and methods
2.1. Bcc strains
Strains used (Table 1) were obtained from the BCCM/LMG
Bacteria Collection (Ghent, Belgium) or were kindly provided by
Dr. P. Vandamme (Ghent University, Belgium). The bacteria
were stored in Microbank tubes (Prolab Diagnostics, Richmond
Hill, ON, Canada) at −80 °C and transferred twice on Mueller
Hinton (MH) (Lab M, Heywood, UK) agar plates before use in
any experiment. All cultivations were performed under aerobic
conditions at 37 °C.Table 1
Bcc strains used in the present study.
Strain Isolation source Tobramycin MIC
(μg/mL)
Burkholderia cenocepacia LMG 16656 CF patient 256
Burkholderia multivorans LMG 13010 CF patient 64
Burkholderia cepacia LMG 1222 Onion 32
Burkholderia anthina LMG 20980 Soil 16
Burkholderia vietnamiensis LMG 10929 Soil 16
Burkholderia metallica LMG 24068 CF patient 642.2. Reagents
A highly purified solution of rhDNase (1.0 mg/mL)
(Pulmozyme, Genentech Inc., San Francisco, CA, USA) which
selectively degrades DNA, was obtained from the pharmacy of
the Ghent University hospital (Ghent, Belgium). It was stored
between 2 and 8 °C, protected from light. A NaClO solution
(4–4.99% available chlorine), was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and stored between 2 and 8 °C
protected from light. Lyophilized dispersin B was obtained from
Kane Biotech Inc. (Winnipeg,MB, Canada) and was dissolved in
equal volumes of glycerol and 100 mMphosphate buffer pH 5.9,
supplemented with 200 mM NaCl. The dispersin B solution was
stored at −20 °C.
2.3. Biofilm formation
An inoculumwas prepared by suspending bacteria from a pure
culture onMH agar inMH broth. The inoculumwas standardized
at ∼108 CFU/mL and the wells of a round-bottomed 96-well
microtiter plate (TPP, Trasadingen, Switzerland) were filled with
100 μL of this standardized bacterial suspension. Plates were
incubated at 37 °C for 4 h without shaking. After 4 h, the
supernatant, containing planktonic cells, was aspirated from the
wells. Adhered cells were carefully washed with 100 μL of
physiological saline (0.9%NaCl) (PS) and 100 μL of fresh sterile
MH broth was added. Plates were incubated for another 20 h at
37 °C without shaking.
2.4. Quantification of eDNA in the biofilm matrix
Eppendorf protein LoBind microcentrifuge tubes (1.5 mL)
(Eppendorf AG, Hamburg, Germany) were inoculated with
600 μL of a standardized bacterial solution (∼108 CFU/mL) in
cation-supplemented MH broth (0.015% (w/v) CaCl2; 2.0 mM
MgCl2) (csMH broth), with or without the addition of rhDNase
(50 μg/mL). Experiments were performed in csMH broth as
Ca2+ and Mg2+ are essential for DNase I activity [16]. Tubes
were incubated aerobically for 4 h at 37 °C without shaking.
After 4 h, the supernatant was gently poured from the tubes to
remove non-adhered planktonic cells. Tubes were rinsed with PS
followed by the addition of 600 μL of fresh sterile csMH broth,
with or without 50 μg/mL rhDNase. After 20 h of additional
incubation, a biofilm had formed on the walls of the tubes
(Supplementary data, Fig. SI) and these were gently rinsed with
PS without disturbing the adherent film. Subsequently, 300 μL of
DNA rehydration solution (Promega, Madison, WI, USA) was
added and biofilms were dispersed in this solvent by vortexing
the tubes.
Biofilm cells were separated from the matrix by centrifugation
at 5000 g for 10 min at 4 °C. The supernatant was aspirated
and filtered through a 0.2 μm cellulose acetate filter (Whatman
GmbH, Dassel, Germany) and the amount of eDNA was
quantified using the Quantifluor dsDNA System kit (Promega,
Madison, WI, USA). eDNA concentrations were normalized to
the number of biofilm cells, determined by plate counting after
24 h of biofilm growth.
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MICs were determined in duplo according to the EUCAST
broth microdilution protocol using unsupplemented MH broth.
In brief, bacterial suspensions were standardized at ∼5 ×
105 CFU/mL before inoculating a flat-bottomed 96-well plate
filled with 100 μL of tobramycin serial dilutions in MH. The
range of tobramycin concentrations used was from 2 to
1024 mg/L. Plates were incubated at 37 °C for 20 h and the
optical density was determined at 590 nm using a multilabel
microtiter plate reader (Envision, Perkin Elmer LAS,Waltham,
MA, USA). The MIC is the lowest concentration of antibiotic
for which a similar optical density was observed in the
inoculated and blank wells.
2.6. Effect of rhDNase on tobramycin susceptibility of 24 h-old
Bcc biofilms
Biofilm formation was carried out in csMH broth with or
without 50 μg/mL of rhDNase. After 24 h, the supernatant was
discarded and biofilms were washed with PS. Subsequently,
100 μL of tobramycin in cation adjusted PS (0.9%NaCl; 0.015%
CaCl2) with or without 50 μg/mL of rhDNase was added. A
tobramycin concentration of 4XMIC was used as previous
research from our group indicated that these concentrations
resulted in a substantial bactericidal effect against Bcc biofilms
[17]. After 24 h of additional incubation at 37 °C, cell numbers
were determined by plate counting.
2.7. Effect of NaClO on tobramycin susceptibility of 24 h-old
Bcc biofilms
Biofilm formation was carried out as described above. After
24 h, the supernatant was aspirated from the wells and biofilms
were washed with PS. Before treatment with tobramycin
(4XMIC in PS), biofilms were exposed to a 15 min pretreatment
with NaOCl (60 μM) (pH 7–8) in phosphate buffered saline
(PBS; pH 7) or with non-supplemented PBS. The NaClO
concentration used was based on the data published by Cuzzi et
al. [5]. Subsequently, biofilms were incubated for another 24 h,
followed by the determination of cell numbers by plate counting.
2.8. Effect of dispersin B on tobramycin susceptibility of
24 h-old Bcc biofilms
After 24 h of biofilm formation, biofilms were washed with
PS and treated either with phosphate buffer (100 mM, pH 5.9),
with phosphate buffer supplemented with tobramycin (4XMIC)
(pH 7) or with phosphate buffer supplemented with tobramycin
(4XMIC) and dispersin B (final concentration of 100 μg/mL)
(pH 7). Plates were incubated for an additional 24 h, followed
by determination of cell numbers by plate counting.
2.9. Statistical analyses
Microtiter plate biofilm assays were performed in 12 wells per
condition and their content was pooled before plate counting. Allexperiments were repeated three times on three separate
occasions (n = 3). Data are represented as means ± SD of the
mean. The significance of differences between treatment groups
was determined using the Mann–Whitney non-parametric test,
with p b 0.05 considered as significant.3. Results
3.1. Quantification of eDNA in biofilm matrix
Biofilms were grown on the walls of Eppendorf tubes for 24 h
in the presence or absence of rhDNase (50 μg/mL) (Fig. SI).
Treatment with rhDNase alone did not lead to dispersion of the
biofilm, as no difference in cell numbers was observed when
biofilms were grown in the presence or absence of rhDNase. The
eDNA content of the biofilm differs considerably between the six
6 Bcc strains investigated, with Burkholderia multivorans LMG
13010 showing the highest amounts (Fig. 1). By adding rhDNase
to the growth medium, a significant reduction in the amount
of eDNA was observed for B. multivorans LMG 13010,
Burkholderia anthina LMG 20980, B. cepacia LMG 1222 and
B. cenocepacia LMG 16656 (Fig. 1). No such difference was
observed after rhDNase treatment for biofilms of Burkholderia
metallica LMG 24068 and B. vietnamiensis LMG 10929.3.2. Effect of rhDNase on tobramycin susceptibility of 24 h-old
Bcc biofilms
rhDNase (50 μg/mL) alone had no effect on the viability or
dispersion of Bcc biofilms (Supplementary data, Fig. SII). The
bactericidal activity of tobramycin was tested in three experi-
mental conditions. Firstly, tobramycin (4XMIC) was added to a
biofilm formed in the presence of 50 μg/mL rhDNase. Secondly,
tobramycin (4XMIC) in combination with 50 μg/mL rhDNase
was added to a biofilm formed in the presence of 50 μg/mL
rhDNase. Finally, tobramycin (4XMIC) was added to a biofilm
formed in the absence of rhDNase. No additional bactericidal
effect, caused by the presence of rhDNase during biofilm treat-
ment and/or during biofilm formation, was observed (Table 2).3.3. Effect of NaClO pretreatment on tobramycin susceptibility
of 24 h-old Bcc biofilms
A short pretreatment of the biofilms with a 60 μM NaClO
solution (pH 7–8) had no bactericidal effect on its own for all
Bcc biofilms tested (Fig. SII). For some Bcc species, tobramycin
(4XMIC) added to NaClO pretreated biofilms resulted in a
significantly increased bactericidal effect compared to tobra-
mycin added to PBS pretreated biofilms (Table 3). The most
pronounced effect of NaClO pretreatment was noticed for
B. metallica LMG 24068, for which an additional 1.42 log
reduction in cell numbers was observed compared to tobramycin
treatment alone. No increased bactericidal effect of tobramycin
was observed in NaClO pretreated B. anthina LMG 20980 and
B. vietnamiensis LMG 10929 biofilms.
Fig. 1. Determination of cell numbers and quantification of eDNA in Burkholderia biofilms. Average amount of eDNA present in the biofilm matrix after 24 h of
growth in the presence and absence of rhDNase. The amount of eDNA was normalized for the number of cells adhered to the tube walls. Error bars represent standard
deviations of 3 independent measurements (n = 3). *: significantly different compared to biofilms grown in the absence of rhDNase (p b 0.05).
59A.-S. Messiaen et al. / Journal of Cystic Fibrosis 13 (2014) 56–623.4. Effect of dispersin B on tobramycin susceptibility of
24 h-old Bcc biofilms
Dispersin B at concentrations of 100 μg/mL had no bacteri-
cidal effect on any Bcc biofilm tested (Fig. SII). The bactericidal
effect of tobramycin dissolved in phosphate buffer (100 mM,
pH 5.9) (Table 4; first row) was significantly reduced compared
to the bactericidal effect of tobramycin dissolved in PS (Tables 2
and 3; first row). Still, for three Bcc isolates, B. cenocepacia
LMG 16656, B. cepacia LMG 1222 and B. metallica LMG
24068, dispersin B significantly increased the bactericidal effect
of tobramycin.Table 2
Average log reductions (±SD) after tobramycin (4XMIC) treatment.
Biofilm formation Biofilm treatment B. cenocepacia
LMG 16656
B. multi
LMG 1
csMH broth Tobramycin 3.87 (±0.13) 3.01 (±
csMH broth + rhDNase Tobramycin 3.75 (±0.19) 3.05 (±
csMH broth + rhDNase Tobramycin + rhDNase 3.66 (±0.18) 2.78 (±
Tobramycin was added to biofilms formed in csMH broth (control), biofilms formed i
presence of rhDNase. No statistically significant difference between the control con4. Discussion
In the present study we investigated the role of different Bcc
biofilm matrix components in the protection against the antimi-
crobial activity of tobramycin. Tobramycin, a positively charged
aminoglycoside antibiotic, is likely to bind to EPS or eDNA,which
will decrease the bioavailability of free tobramycin.
Pulmozyme (a highly purified solution of rhDNase) was
approved in 1993 by the US Food and Drug Administration
(FDA) for the treatment of CF lung disease. rhDNase degrades
eDNA, which is present in large amounts in the sputum of CF
patients, resulting in reduced sputum viscosity and improvedvorans
3010
B. cepacia
LMG 1222
B. anthina
LMG 20980
B. vietnamiensis
LMG 10929
B. metallica
LMG 24068
0.13) 3.14 (±0.37) 4.00 (±0.33) 4.46 (±0.10) 3.55 (±0.18)
0.30) 2.89 (±0.39) 3.70 (±0.33) 4.50 (±0.11) 3.60 (±0.16)
0.08) 2.74 (±0.37) 3.44 (±0.24) 4.17 (±0.16) 3.52 (±0.18)
n csMH broth in the presence of rhDNase and biofilms formed and treated in the
dition and the conditions in which rhDNase was added was observed (n = 3).
Table 3
Average log reductions (±SD) after tobramycin (4XMIC) treatment of biofilms pretreated with PBS or NaOCl.
Pretreatment B. cenocepacia
LMG 16656
B. multivorans
LMG 13010
B. cepacia
LMG 1222
B. anthina
LMG 20980
B. vietnamiensis
LMG 10929
B. metallica
LMG 24068
PBS 3.92 (±0.19) 3.09 (±0.19) 4.01 (±0.13) 3.21 (±0.18) 4.24 (±0.17) 3.83 (±0.22)
NaOCl (60 μM) 4.67 ⁎ (±0.24) 4.25 ⁎ (±0.16) 4.86 ⁎ (±0.13) 3.38 (±0.30) 4.41 (±0.17) 5.25 ⁎ (±0.12)
⁎ : statistically significant difference compared to PBS pretreatment (p b 0.05) (n = 3).
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rhDNase may have an impact on biofilm lung infections. By
degrading eDNA present in the biofilm matrix it could sensitize
bacteria to antibiotic therapy. In the present study we demon-
strated the presence of eDNA in all Bcc biofilms investigated. The
amount of eDNA differed among Bcc strains with the highest
amount of eDNAmeasured for B. multivoransLMG 13010. These
high levels of eDNA could possibly contribute to the virulence of
the bacteria as eDNA has previously been shown to induce
cationic antimicrobial resistance in P. aeruginosa and S. enterica
[13]. rhDNase added at the start of biofilm formation significantly
reduced the amount of eDNA in some Bcc strains. For two Bcc
strains, B. metallica LMG 24068 and B. vietnamiensis LMG
10929 no decrease in eDNA concentration was measured after
rhDNase treatment. Increasing the enzyme concentration could
potentially increase the effect of rhDNase but we did not explore
this further, as the concentrations used (50 μg/mL) were already at
least 5 times higher than the concentrations measured in the
sputum of CF patients after inhalation of 2.5 mg rhDNase I [19].
When added alone, rhDNase had no effect on the viability or
dispersion of Bcc biofilm cells, which is in contrast with the
observations of Tetz and Tetz for Escherichia coli and S. aureus
biofilms [20]. The ability of DNase to disperse established
P. aeruginosa biofilms has also been described [8]. However,
although DNase I was capable of dispersing young biofilms, older
biofilms were much less affected by DNase I, suggesting that other
matrix components became increasingly important in stabilizing
P. aeruginosa biofilms during growth. We subsequently investi-
gated whether rhDNase could increase tobramycin susceptibility
of Bcc biofilm cells. No increased bactericidal effect of tobramycin
was observed if Bcc biofilms were formed in the presence of
50 μg/mL of rhDNase, nor if they were formed and treated in the
presence of rhDNase, which is in agreement with tests previously
performed in CF sputum [21]. Possible explanations are that,
although eDNA is depolymerized by rhDNase, tobramycin can
still bind to small eDNAmolecules or that eDNA is not sufficiently
degraded by rhDNase. Goodman et al. indicated that DNA binding
(DNAB II) proteins contribute to the stabilization and structural
integrity of eDNA within the matrix of different bacterial bio-
films, including Bcc biofilms, which could protect eDNA from
degradation by rhDNase [22,23]. Recently, it has been observedTable 4
Average log reductions (±SD) after tobramycin (4XMIC) treatment alone (controls)
Treatment B. cenocepacia
LMG 16656
B. multivorans
LMG 13010
B.
LM
Tobramycin 0.21 (±0.18) 0.71 (±0.12) 2
Tobramycin + dispersin B 0.46 ⁎ (±0.16) 0.72 (±0.16) 3.0
⁎ : statistically significant difference compared to controls (p b 0.05) (n = 3).that antiserum directed against DNAB II proteins was capable of
reducing B. cenocepacia biofilm mass, sensitizing the biofilm
towards antimicrobials. In contrast, a rhDNase treatment increased
the biofilm biomass [23]. A possible explanation for this is that
smaller eDNA fragments, present in the biofilm matrix after
rhDNase treatment, are increasingly stabilizing the Bcc biofilm
matrix by cross-linking with other exopolymeric substances,
including polysaccharides.
Cepacian is considered the major exopolysaccharide pro-
duced by the isolates of the Bcc [24]. A protective effect of
B. cenocepacia EPS, and more specifically cepacian, towards
ROS has been demonstrated [4]. By scavenging NaClO, the
backbone of cepacian was degraded and acetyl substituents were
cleaved off [5]. The loss of these acetyl substituents hampered the
ability of cepacian chains to aggregate, reducing the viscosity of
the polysaccharide network around Bcc cells [25]. To date, apart
from PNAG, the production of seven different EPS by Bcc
species has been demonstrated. The exact contribution of EPS in
biofilm formation and protection against stress has yet to be
determined [26]. Benincasa et al. already demonstrated a consid-
erable decrease of the antibacterial activity of antimicrobial
peptides in the presence of polysaccharides produced by the
members of the Bcc [27]. To study the effect of cepacian on
tobramycin bioactivity, we pretreated Bcc biofilms with 60 μM
NaClO solution, in order to degrade cepacian, before adding
tobramycin. When combined with tobramycin, we observed a
significantly improved bactericidal activity of the latter against
B. cenocepacia LMG 16656, B. multivorans LMG 13010,
B. cepacia LMG 1222 and B. metallica LMG 24068 biofilms.
On average, 30% less biofilm cells survived after combination
therapy compared to tobramycin alone. The reactivity of ROS is
most likely not limited to the degradation of cepacian but could
also affect the integrity of other EPS. This is corroborated by our
results which demonstrate a significantly increased bactericidal
effect of tobramycin after NaClO pretreatment for B. cenocepacia
LMG 16656, although this strain had previously been shown
not to produce cepacian [28]. The use of a cepacian specific
degrading enzyme, like the cepacian lyase isolated by Cescutti et
al., would allow for better differentiation between the role of
cepacian and other EPS in reducing the activity of tobramycin
[29].or in combination with dispersin B of 24 h-old biofilms.
cepacia
G 1222
B. anthina
LMG 20980
B. vietnamiensis
LMG 10929
B. metallica
LMG 24068
.73 (±0.20) 2.11 (±0.26) 1.22 (±0.20) 2.57 (±0.15)
3 ⁎ (±0.27) 2.06 (±0.23) 1.38 (±0.18) 2.91 ⁎ (±0.14)
61A.-S. Messiaen et al. / Journal of Cystic Fibrosis 13 (2014) 56–62The production of PNAG has been described for
B. multivorans, B. vietnamiensis, Burkholderia ambifaria,
B. cepacia and B. cenocepacia where it seemed to be important
for biofilm formation and maintenance [7]. In addition, a mutant
incapable of producing PNAG showed increased sensitivity to
tobramycin, which suggests a role for PNAG in Bcc antibiotic
resistance [7]. In contrast to these findings of Yakandawala et al.,
we did not observe a biofilm dispersing effect of dispersin B on
Bcc biofilms. The relatively small biofilm killing effect of
tobramycin monotherapy in this experiment is likely attributed
to the buffer recommended for optimal dispersin B activity
(100 mM phosphate buffer supplemented with 200 mM NaCl).
As it has previously been noticed that tobramycin activity can be
significantly reduced in high ionic strength solutions [30], this
could explain the decreased bactericidal effect of tobramycin.
Nevertheless, the combination of dispersin B (100 μg/mL) with
tobramycin significantly increased the latter's bactericidal
effect against B. cenocepacia LMG 16656, B. cepacia LMG
1222 and B. metallica LMG 24068. The combination therapy
resulted in a 10–45% decrease in biofilm cell numbers compared
to tobramycin treatment alone for these isolates.5. Conclusion
We investigated the in vitro bactericidal activity of tobramycin
in combination with matrix degrading substances. rhDNase did
not show any additional effect on antibiotic killing which could
be due to a biofilm stabilizing effect of small eDNA fragments
present in the biofilm matrix after rhDNase treatment. EPS
degradation, by NaClO pretreatment, significantly increased the
bactericidal effect of tobramycin towards some of the Bcc biofilms
tested, as did selective PNAG degradation by dispersin B.Acknowledgments
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